Celldex Therapeutics (NASDAQ:CLDX) Rating Reiterated by Cantor Fitzgerald

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a research report issued on Monday, Benzinga reports. They currently have a $67.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 52.83% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Wolfe Research assumed coverage on shares of Celldex Therapeutics in a research report on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 price target for the company. Stifel Nicolaus initiated coverage on Celldex Therapeutics in a research note on Tuesday, June 18th. They issued a “buy” rating and a $58.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Monday, August 12th. Finally, Wells Fargo & Company increased their target price on shares of Celldex Therapeutics from $35.00 to $37.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $63.83.

Celldex Therapeutics Stock Performance

NASDAQ CLDX traded down $0.32 during trading on Monday, hitting $43.84. The stock had a trading volume of 51,043 shares, compared to its average volume of 763,974. The stock has a 50 day simple moving average of $38.14 and a 200 day simple moving average of $38.87. Celldex Therapeutics has a one year low of $22.11 and a one year high of $53.18. The stock has a market capitalization of $2.91 billion, a price-to-earnings ratio of -15.38 and a beta of 1.56.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.05. The firm had revenue of $2.50 million during the quarter, compared to analyst estimates of $1.13 million. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. On average, sell-side analysts predict that Celldex Therapeutics will post -2.5 EPS for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

A number of large investors have recently bought and sold shares of the company. Arizona State Retirement System lifted its stake in Celldex Therapeutics by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 16,231 shares of the biopharmaceutical company’s stock valued at $601,000 after acquiring an additional 325 shares during the period. Los Angeles Capital Management LLC raised its holdings in shares of Celldex Therapeutics by 9.5% during the second quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 638 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 955 shares during the last quarter. Principal Financial Group Inc. grew its position in Celldex Therapeutics by 10.0% during the 1st quarter. Principal Financial Group Inc. now owns 13,153 shares of the biopharmaceutical company’s stock worth $552,000 after purchasing an additional 1,194 shares during the period. Finally, Fisher Asset Management LLC raised its stake in shares of Celldex Therapeutics by 6.2% during the 4th quarter. Fisher Asset Management LLC now owns 21,812 shares of the biopharmaceutical company’s stock valued at $865,000 after buying an additional 1,274 shares during the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.